Česky
To clarify, SENIMED is also becoming a pharmaceutical company and will continue to import, sell and distribute both OTC and prescription products. SENIMED is now taking over Aurovitas' existing stock. "In the future, we would like to continue in the appropriate selection and expansion of prescription-bound products, which will be carefully considered and selected according to the needs of the Czech market," explained Sales Director Irini Szentiványi.
Aurobindo, operating on the Czech market since 2019 under the name Aurovitas, bought out selected branches of Canadian multinational Apotex after the tragic death of the owner. The latter had long been one of the top 10 generic companies on the Czech market.
Aurovitas brought more than 70 products to market and was one of the most dynamic companies in terms of growth in prescription-linked products. OTC products such as Colafit and Betaglucan from top Czech suppliers or products such as Hedelix, Bromhexin and others from the German company Krewel Meuselbach have a stable position and market share on the market.
Therefore, SENIMED will start supplying the original products of Apotex and Aurovitas to other pharmacies. "Since April, we have smoothly continued all existing collaborations and are continuing our business without interruption, as all our clients have been accustomed to," said the sales director.
"Our goal is to contribute to the prosperity of SENIMED, or AKESO holding, and to create a company with a stable background and an expanding portfolio of products, whether over-the-counter or prescription-bound," said CEO Martina Antenova. "Today, it is admirable what Mr. Sotirios Zavalianis has achieved with his own care and empathy. This was a motivating factor for us to join our paths. We admire that all his profits are reinvested in the improvement of the Czech healthcare system and patient comfort," added Irini Szentiványi as to why the merger of the two companies took place.
